# Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours

> **NCT00716417** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 47 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT00716417
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-01
- **Primary completion:** 2010-07-01
- **Final completion:** 2010-07-01
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00716417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00716417, "Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00716417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*